William Lumry

Jan 8, 2024 | healio.com | Richard Gawel |Kristen Dowd |Douglas H. Jones |William Lumry

Douglas H. Jones, MD Overall, these results are promising, as they show safety and efficacy for an oral medication to be used prophylactically in patients with HAE who have previously only had parenteral options available. These results also are consistent with what I have experienced with my patients. Many of our HAE patients are “needle fatigued,” since only intravenous or subcutaneous medications have been available previously. In my experience, that can lead to a tendency for noncompliance.